F M Moinuddin1,2, Mohammed Ali Alvi1,2, Panagiotis Kerezoudis1,2, Waseem Wahood1,2, Jenna Meyer3, Daniel Honore Lachance4, Mohamad Bydon5,6. 1. Mayo Clinic Neuro-Informatics Laboratory, Mayo Clinic College of Medicine and Science, Rochester, MN, 55902, USA. 2. Department of Neurologic Surgery, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55902, USA. 3. Faculty of Health Sciences, Medical School for International Health, Ben-Gurion University fo the Negev, Be'er Sheva, 84105, Israel. 4. Department of Neurology, Mayo Clinic, Rochester, MN, 55902, USA. 5. Mayo Clinic Neuro-Informatics Laboratory, Mayo Clinic College of Medicine and Science, Rochester, MN, 55902, USA. bydon.mohamad@mayo.edu. 6. Department of Neurologic Surgery, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55902, USA. bydon.mohamad@mayo.edu.
Abstract
PURPOSE: Primary glioblastoma of the spinal cord (spinal GBM) is a rare central nervous system tumor, relative to its cranial counterpart (cranial GBM). Our current knowledge of spinal GBM epidemiology, tumor characteristics and treatment are insufficient and mostly based on single-institution case series. METHODS: All patients diagnosed with grade-4 GBM from 2004 to 2014 were queried from the National Cancer Database. Chi square analysis was used to compare presenting characteristics while Kaplan-Meier and Cox regression analyses were employed for survival analyses. RESULTS: Total 103,496 patients with cranial GBM and 190 patients with spinal GBM were analyzed. Median survival for spinal GBM was found to be higher compared to cranial GBM (p = 0.07). Spinal GBM patients had significant better survival in 18 to 65 years age group than < 18 years and > 65 years age group (p = 0.003). Overall survival time for 95 spinal GBM patients with available treatment data was not statistically different among the four treatment modalities (radiation with or without chemotherapy, surgery alone, surgery with adjuvant therapy, and palliative therapy; p = 0.28).On multivariable analysis, < 18 years age group was associated with improved survival (HR 0.50, 95% CI 0.23-1.00, p = 0.046), while tumor extension was associated with poor survival (HR 2.71, 95% CI 1.04-6.22, p = 0.041). Interestingly surgery with adjuvant therapy was unable to show increase survival compared to other treatment modalities. CONCLUSIONS: Our study adds to the growing literature on spinal GBM with a focus on comparative trends with cranial GBM and outcomes with different treatment modalities.
PURPOSE: Primary glioblastoma of the spinal cord (spinal GBM) is a rare central nervous system tumor, relative to its cranial counterpart (cranial GBM). Our current knowledge of spinal GBM epidemiology, tumor characteristics and treatment are insufficient and mostly based on single-institution case series. METHODS: All patients diagnosed with grade-4 GBM from 2004 to 2014 were queried from the National Cancer Database. Chi square analysis was used to compare presenting characteristics while Kaplan-Meier and Cox regression analyses were employed for survival analyses. RESULTS: Total 103,496 patients with cranial GBM and 190 patients with spinal GBM were analyzed. Median survival for spinal GBM was found to be higher compared to cranial GBM (p = 0.07). Spinal GBM patients had significant better survival in 18 to 65 years age group than < 18 years and > 65 years age group (p = 0.003). Overall survival time for 95 spinal GBM patients with available treatment data was not statistically different among the four treatment modalities (radiation with or without chemotherapy, surgery alone, surgery with adjuvant therapy, and palliative therapy; p = 0.28).On multivariable analysis, < 18 years age group was associated with improved survival (HR 0.50, 95% CI 0.23-1.00, p = 0.046), while tumor extension was associated with poor survival (HR 2.71, 95% CI 1.04-6.22, p = 0.041). Interestingly surgery with adjuvant therapy was unable to show increase survival compared to other treatment modalities. CONCLUSIONS: Our study adds to the growing literature on spinal GBM with a focus on comparative trends with cranial GBM and outcomes with different treatment modalities.
Authors: Herbert H Engelhard; J Lee Villano; Kimberly R Porter; Andrew K Stewart; Manali Barua; Fred G Barker; Herbert B Newton Journal: J Neurosurg Spine Date: 2010-07
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Albert P Wong; Nader S Dahdaleh; Richard G Fessler; Stephanie C Melkonian; Yimo Lin; Zachary A Smith; Sandi K Lam Journal: J Neurooncol Date: 2013-09-29 Impact factor: 4.130
Authors: Li-Nien Chien; Haley Gittleman; Quinn T Ostrom; Kuo-Sheng Hung; Andrew E Sloan; Yi-Chen Hsieh; Carol Kruchko; Lisa R Rogers; Ye-Fan Glavin Wang; Hung-Yi Chiou; Jill S Barnholtz-Sloan Journal: Front Public Health Date: 2016-07-21
Authors: Benjamin J Delgado; Leila Moosavi; Ericka Rangel; William Stull; Rahul Dev Polineni; Joseph Chen; Everardo Cobos Journal: J Investig Med High Impact Case Rep Date: 2019 Jan-Dec
Authors: Vicki M Butenschoen; Vanessa Hubertus; Insa K Janssen; Julia Onken; Christoph Wipplinger; Klaus C Mende; Sven O Eicker; Victoria Kehl; Claudius Thomé; Peter Vajkoczy; Karl Schaller; Jens Gempt; Bernhard Meyer; Maria Wostrack Journal: J Neurooncol Date: 2020-10-22 Impact factor: 4.130